One-Shot cell therapy aims to reset immune system in devastating scleroderma
NCT ID NCT07493395
Summary
This early-stage trial is testing whether a single infusion of a patient's own genetically modified immune cells (CAR T-cells) can reduce disease activity in adults with severe systemic sclerosis (scleroderma) that hasn't responded to other treatments. The study will enroll 6 participants to primarily check if the therapy is safe and if it improves skin thickening and other symptoms. Patients will be closely monitored for two years after the one-time infusion to see how their bodies respond.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLERODERMA, SYSTEMIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
APHP Necker
Paris, France
Contact
Contact Email: •••••@•••••
-
CHRU Lille
Lille, France
Contact Email: •••••@•••••
Contact
-
Chu Rouen
Rouen, France
Contact Email: •••••@•••••
-
Montpellier University Hospital
Montpellier, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.